At OPEN Health, the excitement is building for pH Associates and OPEN Access Consulting as they prepare for their imminent return to ISPOR’s Annual European Congress, from 6th 8th November in Glasgow.
Both pH Associates and OPEN Access Consulting are proud to be presenting 15 posters this year, including four of which have been nominated as ISPOR Research Presentation Award Finalists:
- Work productivity in HER2 positive breast cancer: a comparison of patients across stages of early and metastatic disease (PCN234)
- A multi-centre retrospective study to describe the impact on healthcare resource use and real world effectiveness of golimumab in ankylosing spondylitis (AS) in UK clinical practice (PMS97)
- The use of real world evidence data for NICE decision-making: a review of submissions to three treatment effectiveness evaluation programmes in 2015 and 2016 (PHP239)
- Does the early bird catch the worm? Early cancer detection and survival in the UK (PHS77)
Come and visit them at ISPOR Stand 105, where they will be delighted to discuss your Real World Evidence and Market Access needs. Have your say about Real World Evidence Gaps at Stand 105, where they will be running an interactive survey. Evidence is only as strong as its weakest gap; pH Associates and OPEN Access Consulting want to learn more about what’s driving or dragging your real world evidence initiatives.
A few minutes of your time can make a difference as pH Associates and OPEN Access Consulting will make a donation to our specially chosen charity: Médecins Sans Frontières (Doctors Without Borders), the international humanitarian organisation, known particularly for providing medical aid in war-torn regions and developing countries.
You can also find out about some of the exciting things we have been up to recently, including the launch of REAL Europe - A brand new alliance between pH and specialist Real World Evidence partners in Europe, allowing pH to strengthen their capabilities in Europe and beyond, designing bespoke RWE studies for a global audience.